More than half of all generics are still placed on non-generic Medicare Part D plan tiers, finds consulting firm Avalere in its latest analysis, which was funded by the American off-patent group Association for Accessible Medicines.
In 2024, 56.2% of generic drugs were placed not on their designated tiers, marking the fifth year of this trend. But while the proportion of generic drugs placed on non-generic tiers increased over the years, it has stabilized in recent years